Stock Events

Stock Events

Clinuvel Pharmaceuticals

€0

0

+€0+0% Today

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

25FebExpected

Q4 2025

0.12

0.13

0.15

0.17

Expected EPS

0.16525896168235998

Actual EPS

0.11651557666699999

People Also Follow

This list is based on the watchlists of people on Stock Events who follow UR9.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

ICON plc provides clinical research services to the pharmaceutical, biotechnology, and medical device industries, competing in the development and commercialization of dermatological treatments similar to Clinuvel's focus.

Pfizer Inc. is involved in the discovery, development, manufacture, marketing, sales, and distribution of biopharmaceutical products, including treatments in areas that overlap with Clinuvel's therapeutic focus.

Merck & Co., Inc. offers health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products, competing in areas such as skin conditions and rare diseases.

Novartis AG researches, develops, manufactures, and markets healthcare products in areas that compete with Clinuvel, including dermatology and rare diseases.

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, including skin health products that compete with Clinuvel's portfolio.

Johnson & Johnson

Johnson & Johnson researches and develops, manufactures, and sells a broad range of products in the healthcare field, including competitive offerings in dermatology and rare diseases.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products directly competing in the dermatology and rare disease market segments targeted by Clinuvel.

Amgen Inc. focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise, competing in the development of treatments for conditions that Clinuvel also targets.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions, including skin diseases.

Biomarin Pharmaceutical

BioMarin Pharmaceutical Inc. develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, including rare genetic diseases that overlap with Clinuvel's focus areas.

About

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Show more...

CEO

Dr. Philippe Jacques Wolgen M.B.A., M.D.

Country

United States

ISIN

AU000000CUV3

Listings

0 Comments

Share your thoughts

FAQ

What is Clinuvel Pharmaceuticals stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Clinuvel Pharmaceuticals stocks are traded under the ticker UR9.MU.

When is the next Clinuvel Pharmaceuticals earnings date?▼

Clinuvel Pharmaceuticals is going to release the next earnings report on September 01, 2026.

What were Clinuvel Pharmaceuticals earnings last quarter?▼

UR9.MU earnings for the last quarter are 0.12 EUR per share, whereas the estimation was 0.17 EUR resulting in a -29.5% surprise. The estimated earnings for the next quarter are N/A EUR per share.

In which sector is Clinuvel Pharmaceuticals located?▼

Clinuvel Pharmaceuticals operates in the Health & Wellness sector.

When did Clinuvel Pharmaceuticals complete a stock split?▼

Clinuvel Pharmaceuticals has not had any recent stock splits.

Where is Clinuvel Pharmaceuticals headquartered?▼

Clinuvel Pharmaceuticals is headquartered in Melbourne, United States.